NeoGenomics (NASDAQ:NEO) Stock Gets Price Target Increase from Needham & Company LLC

Posted by Brian Himes on Oct 8th, 2026

NeoGenomics (NASDAQ:NEO – Get Free Report) had its target price hoisted by analysts at Needham & Company LLC from $19.00 to $22.00 in a note issued to investors on Tuesday, MarketBeat.com reports. The brokerage currently has a “buy” rating on the medical research company’s stock. Needham & Company LLC’s price target suggests a potential upside of 37.76% from the company’s current price.

A number of other research firms have also recently weighed in on NEO. Craig Hallum restated a “buy” rating and issued a $19.00 price target on shares of NeoGenomics in a research note on Wednesday, July 29th. Zacks Research downgraded shares of NeoGenomics from a “strong-buy” rating to a “hold” rating in a report on Monday, September 28th. Benchmark increased their price objective on shares of NeoGenomics from $11.00 to $16.00 and gave the company a “buy” rating in a research report on Friday, July 24th. TD Cowen reaffirmed a “buy” rating on shares of NeoGenomics in a report on Wednesday, July 15th. Finally, Wall Street Zen raised shares of NeoGenomics from a “hold” rating to a “buy” rating in a report on Saturday, June 27th. Six investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $18.17.

Read Our Latest Analysis on NEO

NeoGenomics Stock Down 3.2%

NeoGenomics stock opened at $15.97 on Tuesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.60 and a quick ratio of 3.35. The company’s 50-day moving average is $17.47 and its 200-day moving average is $13.00. The firm has a market capitalization of $2.05 billion, a PE ratio of -39.92 and a beta of 1.79. NeoGenomics has a fifty-two week low of $7.07 and a fifty-two week high of $20.15.

NeoGenomics (NASDAQ:NEO – Get Free Report) last posted its quarterly earnings results on Tuesday, July 28th. The medical research company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.02. The business had revenue of $201.66 million during the quarter, compared to analysts’ expectations of $196.93 million. NeoGenomics had a negative return on equity of 1.99% and a negative net margin of 6.77%.NeoGenomics’s quarterly revenue was up 11.2% on a year-over-year basis. During the same quarter last year, the company posted $0.03 earnings per share. Sell-side analysts anticipate that NeoGenomics will post -0.09 earnings per share for the current year.

Hedge Funds Weigh In On NeoGenomics

Hedge funds and other institutional investors have recently modified their holdings of the business. First Light Asset Management LLC boosted its stake in NeoGenomics by 26.2% in the second quarter. First Light Asset Management LLC now owns 12,279,523 shares of the medical research company’s stock valued at $179,158,000 after buying an additional 2,549,545 shares in the last quarter. WINTON GROUP Ltd acquired a new position in NeoGenomics during the second quarter worth about $925,000. Integrated Wealth Concepts LLC acquired a new stake in shares of NeoGenomics in the 2nd quarter valued at approximately $99,000. NewEdge Advisors LLC acquired a new stake in NeoGenomics in the second quarter valued at approximately $296,000. Finally, Squarepoint Ops LLC boosted its stake in shares of NeoGenomics by 118.3% during the second quarter. Squarepoint Ops LLC now owns 222,036 shares of the medical research company’s stock valued at $3,240,000 after purchasing an additional 120,342 shares in the last quarter. Institutional investors own 98.50% of the company’s stock.

Key Headlines Impacting NeoGenomics

Here are the key news stories impacting NeoGenomics this week:

Positive Sentiment: BTIG upgraded NeoGenomics to Buy from Neutral, signaling improved confidence in the company’s outlook. BTIG upgrades NeoGenomics to Buy
Positive Sentiment: Needham raised its price target to $22 from $19 and maintained a Buy rating, implying substantial upside from the referenced share price. Needham raises NeoGenomics price target
Positive Sentiment: NeoGenomics issued third-quarter 2026 revenue guidance of $209 million, above the $205.8 million consensus estimate. Full-year revenue guidance of $802 million to $806 million was broadly in line with the $803.8 million consensus. The company’s latest reported quarter also exceeded revenue and EPS expectations, with revenue up 11.2% year over year.
Positive Sentiment: Warren Stone was selected as the next CEO, providing a named successor and potentially reducing some uncertainty around the transition. Warren Stone named next NeoGenomics CEO
Neutral Sentiment: Board changes are scheduled to take effect January 4, 2027, adding another governance transition for investors to monitor. NeoGenomics board changes
Negative Sentiment: The stock fell sharply after the CEO succession announcement, despite the revenue beat and solid outlook. Investors appear concerned about execution risk, strategic continuity, and whether the leadership change could disrupt NeoGenomics’ growth trajectory. NeoGenomics falls on CEO succession plan

NeoGenomics Company Profile

(Get Free Report)

NeoGenomics, Inc (NASDAQ:NEO) is a specialized oncology diagnostics company that provides testing services to hospitals, physicians, pathologists, pharmaceutical companies and other healthcare organizations. Its services support the diagnosis, classification and monitoring of cancer, helping guide treatment decisions and drug development.

The company offers a broad range of pathology and laboratory services, including molecular testing, next-generation sequencing, fluorescence in situ hybridization, cytogenetics, flow cytometry, immunohistochemistry and digital pathology.